AGAP2 and neoplasm: As previously documented, AGAP2-AS1 may be a clinical biomarker for subsequent tumor progression in "low-risk" ccRCC patients [17], and it may also serve as an independent predictor of unfavorable outcomes of ccRCC patients [18].